Search Patents
-
Patent number: 7803918Abstract: A new coronavirus is disclosed herein with a tropism that includes humans. Means and methods are provided for diagnosing subjects (previously) infected with the virus. Also provided are among others vacines, medicaments, nucleic acids and specific binding members.Type: GrantFiled: August 18, 2004Date of Patent: September 28, 2010Assignee: Amsterdam Institute of Viral Genomics B.V.Inventor: Cornelia van der Hoek
-
Publication number: 20080206283Abstract: The present invention provides nucleotide sequences from SARS (Serve Acute Respiratory Syndrome) coronavirus genomes, as well as the applications of the partial fragments thereof in preparing DNA vaccine or expressing corresponding proteins. Furthermore, the present invention also provides the uses of said proteins in preventing and treating diseases, and preparing antibodies.Type: ApplicationFiled: June 17, 2004Publication date: August 28, 2008Inventors: Xiangjun Zhou, John Y. Dong
-
Patent number: 7429656Abstract: The present invention relates to therapeutic agents useful for the treatment of Severe Acute Respiratory Syndrome (SARS) in humans. In particular, the present invention relates to RNA interference (RNAi) molecules useful for inhibiting the infection and replication of hSARS virus. Preferably, the RNAi molecules target the replicase region of the hSARS virus, or combinations of different sites of hSARS virus genes. The present invention further encompasses methods of using the RNAi molecules for preventing and/or treating SARS. Vaccines and kits comprising therapeutically effective amounts of the RNAi molecules are also encompassed.Type: GrantFiled: June 14, 2006Date of Patent: September 30, 2008Assignee: The University of Hong KongInventors: Hsiang-Fu Kung, Ming-Liang He, Bo-Jiang Zheng, Yi Guan, Marie Chia-Mi Lin, Ying Peng
-
Publication number: 20110065089Abstract: The invention relates to a novel strain of severe acute respiratory syndrome (SARS)-associated coronavirus, resulting from a sample collected in Hanoi (Vietnam), reference number 031589, nucleic acid molecules originating from the genome of same, proteins and peptides coded by said nucleic acid molecules and, more specifically, protein N and the applications thereof, for example, as diagnostic reagents and/or as a vaccine.Type: ApplicationFiled: April 6, 2010Publication date: March 17, 2011Inventors: Sylvie Van Der Werf, Nicolas Escriou, Bernadette Crescenzo-Chaigne, Jean-Claude Manuguerra, Frederik Kunst, Benoît Callendret, Jean-Michel Betton, Valérie Lorin, Sylvie Gerbaud, Ana Maria Burguiere, Saliha Azebi, Pierre Charneau, Frédéric Tangy, Chantal Combredet, Jean-François Delagneau, Monique Martin
-
Patent number: 7736850Abstract: The invention relates to a novel strain of severe acute respiratory syndrome (SARS)-associated coronavirus, resulting from a sample collected in Hanoi (Vietnam), reference number 031589, nucleic acid molecules originating from the genome of same, proteins and peptides coded by said nucleic acid molecules and, more specifically, protein N and the applications thereof, for example, as diagnostic reagents and/or as a vaccine.Type: GrantFiled: December 2, 2004Date of Patent: June 15, 2010Assignees: Institute Pasteur, Centre National de la Recherche Scientifique, Universite Paris 7Inventors: Sylvie Van Der Werf, Nicolas Escriou, Bernadette Crescenzo-Chaigne, Jean-Claude Manuguerra, Frederick Kunst, Benoît Callendret, Jean-Michel Betton, Valérie Lorin, Sylvie Gerbaud, Ana Maria Burguiere, Saliha Azebi, Pierre Charneau, Frédéric Tangy, Chantal Combredet, Jean-François Delagneau, Monique Martin
-
Publication number: 20110142879Abstract: Methods of preparing a DNA comprising sequences derived from the genomic RNA (gRNA) of a coronavirus are provided, comprising cloning under the expression of a promoter a coronavirus interfering defective genome into a bacterial artificial chromosome (BAC) and reinserting into said genome the deleted sequences within the defective genome, wherein said sequences have a homology of at least 60% to the natural sequence of the virus, wherein said sequences code for an RNA-dependent RNA polymerase and at least one structural or non-structural protein, and wherein a fragment of said DNA is capable of being transcribed into RNA and assembeld to a virion. Also provided are infective clones, recombinant viral vectors, and vaccines.Type: ApplicationFiled: November 3, 2010Publication date: June 16, 2011Applicant: CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICASInventor: LUIS ENJUANES SANCHEZ
-
Patent number: 8092994Abstract: The present invention provides the complete genomic sequence of a novel human coronavirus, coined as coronavirus-HKU1 (“CoV-HKU1”), isolated in Hong Kong from a patient who had a recent history of visit to Schenzhen, China. The virus belongs to the order Nidovirales of the family Coronavirdae, being a single-stranded RNA virus of positive polarity. The invention also provides the deduced amino acid sequences of the complete genome of the CoV-HKU1. The nucleotide sequences and deduced amino acid sequences of the CoV-HKU1 are useful in preventing, diagnosing and/or treating the infection by CoV-HKU1. Furthermore, the invention provides immunogenic and vaccine preparations using recombinant and chimeric forms as well as subunits of the CoV-HKU1 based on the nucleotide sequences and deduced amino acid sequences of the CoV-HKU1.Type: GrantFiled: June 1, 2009Date of Patent: January 10, 2012Assignee: Versitech LimitedInventors: Kwok Yung Yuen, Chiu Yat Patrick Woo, Kar Pui Susanna Lau, Kwok Hung Chan, Lit Man Poon, Joseph Sriyal Malik Peiris, Yi Guan
-
Patent number: 7553944Abstract: The present invention provides the complete genomic sequence of a novel human coronavirus, coined as coronavirus-HKU1 (“CoV-HKU1”), isolated in Hong Kong from a patient who had a recent history of visit to Schenzhen, China. The virus belongs to the order Nidovirales of the family Coronaviridae, being a single-stranded RNA virus of positive polarity. The invention also provides the deduced amino acid sequences of the complete genome of the CoV-HKU1. The nucleotide sequences and deduced amino acid sequences of the CoV-HKU1 are useful in preventing, diagnosing and/or treating the infection by CoV-HKU1. Furthermore, the invention provides immunogenic and vaccine preparations using recombinant and chimeric forms as well as subunits of the CoV-HKU1 based on the nucleotide sequences and deduced amino acid sequences of the CoV-HKU1.Type: GrantFiled: July 21, 2004Date of Patent: June 30, 2009Assignee: The University of Hong KongInventors: Kwok Yung Yuen, Chiu Yat Patrick Woo, Kar Pui Susanna Lau, Kwok Hung Chan, Lit Man Poon, Joseph Sriyal Malik Peiris, Yi Guan
-
Patent number: 7371837Abstract: The present invention provides the complete genomic sequence of a novel human coronavirus, coined as human coronavirus-HKU1 (“CoV-HKU1”), isolated in Hong Kong. The virus belongs to the order Nidovirales of the family Coronaviridae, being a single-stranded RNA virus of positive polarity. Further study on nasopharyngeal aspirates from patients with community-acquired pneumonia has revealed that there are two genotypes, genotype A and genotype B, for this virus. In addition to the genomic sequences of these two genotypes, the invention provides the deduced amino acid sequences of the complete genome of the CoV-HKU1. The nucleotide sequences and deduced amino acid sequences of the CoV-HKU1 are useful in preventing, diagnosing and/or treating the infection by CoV-HKU1. Furthermore, the invention provides immunogenic and vaccine preparations using recombinant and chimeric forms as well as subunits of the CoV-HKU1 based on the nucleotide sequences and deduced amino acid sequences of the CoV-HKU1.Type: GrantFiled: May 16, 2005Date of Patent: May 13, 2008Assignee: The University of Hong KongInventors: Kwok Yung Yuen, Chiu Yat Patrick Woo, Kar Pui Susanna Lau, Kwok Hung Chan
-
Publication number: 20080081047Abstract: Monoclonal antibody reagents that recognize the SARS-coronavirus (SARS-HCoV) are needed urgently. In this report we describe the development and immunochemical characterisation of mAbs against the SARS-HCoV based upon their specificity, binding requirements, and biological activity. Initial screening by ELISA, using highly purified virus as the coating antigen, resulted in the selection of seventeen mAbs. Five mAbs exhibited Western immunoblot reactivity with the denatured spike protein, of which two demonstrated the ability to neutralize SARS-HCoV in vitro. Another four Western immunoblot-negative mAbs also neutralize the virus. These antibodies will be useful for the development of diagnostic tests, pathogenicity and vaccine studies.Type: ApplicationFiled: December 6, 2004Publication date: April 3, 2008Inventors: Jody Berry, Steven Jones, Xin Yong Yuan, Mike Gubbins, Anton Andonov, Hana Weingartl, Mike Drebot, Frank Plummer
-
Patent number: 7361747Abstract: The present invention relates to isolation and characterization of a class of isolated novel viruses which is the precursor of the virus causing Severe Acute Respiratory Syndrome (SARS) in humans (“hSARS virus”). The precursor virus which is a SARS coronavirus-like virus (“SCoV-like virus”) is identified to be morphologically and phylogenetically similar to hSARS virus. The present invention relates to a nucleotide sequence comprising the genomic sequence of the SCoV-like virus. The invention further relates to nucleotide sequences comprising a portion of the genomic sequence of the SCoV-like virus. The invention also relates to the deduced amino acid sequences of the SCoV-like virus. The invention further relates to the nucleic acids and peptides encoded by and/or derived from these sequences and their use in diagnostic methods and therapeutic methods.Type: GrantFiled: May 24, 2004Date of Patent: April 22, 2008Assignee: The University of Hong KongInventors: Yi Guan, Bo-Jiang Zheng